Skip to Main

Srikant Vaidyanathan joined Boston Consulting Group in 2003 and has worked in the Chicago and Zurich offices. He is a core member of the firm’s Health Care; Marketing, Sales & Pricing; and Operations practices. He leads BCG’s market access and pricing sector worldwide and is an expert in technial operations across the value chain in both small molecules and biologics.

Before joining BCG, Srikant worked at Corning in the US for five years. While there, he took several products from concept to market. He has contributed to publications from the Health Care and People & Organization practices.

AREAS OF EXPERTISE

EDUCATION

  • PhD, materials, University of California, Santa Barbara
  • MS, University of Virginia School of Engineering and Applied Science
  • BTech, Indian Institute of Technology Bombay

HONORS AND AWARDS

  • Holds more than 40 patents

Publications and Videos

" "

Two Ways Genomic Sequencing Could Reshape Advanced Diagnostics

Costs for genomic sequencing have dropped steeply, making new types of genetic tests more accessible and changing the business model for the labs that run them.
" "

Making Medtech More Equitable

By developing products for a broader base of patients and markets, medtech companies can improve health outcomes, generate business advantages, and contribute to healthier societies overall.
Integrating Health Equity Across a Biopharma Organization | Rectangle

Embedding Health Equity into the Heart of Biopharma

The biopharma industry faces demands for more action to address health inequities. We provide a guide and tools to help companies integrate equity across the product lifecycle.
" "

The Future of Integrated Evidence Planning in Biopharma

Biopharma companies can promote the success of product launches by initiating cross-functional collaboration on evidence generation early in the development process.
Improving Care in Immune-Mediated Diseases | rectangle

Improving Care in Immune-Mediated Diseases

To become leaders in the field, biopharma companies must understand unmet needs and evolving standards of care and make greater use of real-world evidence.
It’s Time for CFOs to Embrace Agile

It’s Time for CFOs to Embrace Agile

Contrary to what skeptics believe, it’s not necessary to go all in when applying agile methods. A selective approach can promote efficiency and effectiveness.
Nurse sitting at desk typing on keyboard

How Pharma Can Navigate the Shifting Sands of Oncology Treatments

With advances in knowledge, understanding, technology, and data come fragmentation and complexity. Since the bets are big, companies need to evaluate prospects and make their investments count.
Competing in China’s Booming Biopharma Market - square

Competing in China’s Booming Biopharma Market

Multinational companies need to map a strategy to tap into China’s growth—and compete with increasingly innovative “homegrown” Chinese biopharma companies.
agile-in-pharma-rectangle-opt.jpg

Agile Can Work Wonders in Pharma

Even highly regulated and rigid industries can benefit from new ways of working.
switzerland-80284469-tcm9-194929.jpg

Switzerland’s Appeal Endures Despite a Dip

The country gets its shine from a strong job market—but new immigration policies have eroded its star standing.
challenge-pricing-combination-1694x950-tcm9-81462.jpg

The Challenge of Pricing Combination Therapies

Pharmaceutical companies are seeking approval of more combination therapies, but setting prices for the various products that make up those treatments is exceedingly complex.